Department of Obstetrics and Gynaecology, Lady Davis Carmel Medical Center, Haifa, Israel.
Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
BJOG. 2016 Oct;123(11):1779-86. doi: 10.1111/1471-0528.13723. Epub 2015 Nov 10.
To assess the impact of antenatal corticosteroid therapy on mortality and severe morbidities in preterm, small-for-gestational-age (SGA) neonates compared with preterm non-SGA neonates.
Population-based study.
SETTING/POPULATION: Israel National Very Low Birth Weight infant database from 1995-2012.
Singleton infants of 24-31 weeks' gestation, without major malformations. Antenatal corticosteroids were considered either any treatment or no treatment.
Univariate and multivariable logistic regression analyses were performed to assess the effect of antenatal corticosteroids on neonatal mortality and a composite adverse outcome of mortality or severe neonatal morbidity.
Among the 10 887 study infants, 1771 were SGA. Of these, 70.4% of SGA and 66.7% of non-SGA neonates were exposed to antenatal corticosteroids. Among SGA neonates, antenatal corticosteroids were associated with decreased mortality (32.2 versus 19.3%, P < 0.0001) and composite adverse outcome (54.1 versus 43.4%, P < 0.0001), similar to the effect in non-SGA neonates (mortality 26.7 versus 12.2%, P < 0.0001; composite outcome 50.5 versus 34.6%, P < 0.0001). Multivariable logistic regression analyses demonstrated a 50% reduction in mortality risk among SGA and 57% reduction in non-SGA neonates exposed to corticosteroids [OR = 0.50, 95% confidence interval (95% CI) 0.39-0.64 and OR = 0.43, 95% CI 0.38-0.47, respectively], P-value for interaction = 0.08. Composite adverse outcome risk was significantly reduced in SGA (OR = 0.67, 95% CI 0.54-0.83) and non-SGA infants (OR = 0.57, 95% CI 0.52-0.63), P-value for interaction = 0.04.
Antenatal corticosteroids significantly reduced mortality and severe morbidities among preterm SGA neonates, with slightly a less pronounced effect compared with non-SGA preterm infants. Antenatal corticosteroids should be given to fetuses suspected of intrauterine growth retardation, at risk for preterm delivery, in order to improve perinatal outcome.
Antenatal steroids reduced mortality and severe morbidities among singleton, preterm SGA neonates.
评估产前皮质类固醇治疗对小于胎龄儿(SGA)早产儿与非 SGA 早产儿的死亡率和严重并发症的影响。
基于人群的研究。
设置/人群:1995 年至 2012 年以色列国家极低出生体重儿数据库。
24-31 周妊娠的单胎婴儿,无重大畸形。产前皮质类固醇被认为是有治疗或无治疗。
采用单变量和多变量逻辑回归分析评估产前皮质类固醇对新生儿死亡率和死亡率或严重新生儿并发症的复合不良结局的影响。
在 10887 名研究婴儿中,有 1771 名是 SGA。其中,70.4%的 SGA 和 66.7%的非 SGA 新生儿接受了产前皮质类固醇治疗。在 SGA 新生儿中,产前皮质类固醇治疗与死亡率降低相关(32.2%比 19.3%,P<0.0001)和复合不良结局(54.1%比 43.4%,P<0.0001),与非 SGA 新生儿的效果相似(死亡率 26.7%比 12.2%,P<0.0001;复合结局 50.5%比 34.6%,P<0.0001)。多变量逻辑回归分析显示,接受皮质类固醇治疗的 SGA 早产儿和非 SGA 早产儿的死亡率风险分别降低了 50%(OR=0.50,95%置信区间[95%CI]为 0.39-0.64)和 57%(OR=0.43,95%CI 为 0.38-0.47),P 值交互作用=0.08。SGA(OR=0.67,95%CI 为 0.54-0.83)和非 SGA 婴儿(OR=0.57,95%CI 为 0.52-0.63)的复合不良结局风险显著降低,P 值交互作用=0.04。
产前皮质类固醇可显著降低 SGA 早产儿的死亡率和严重并发症,与非 SGA 早产儿相比,效果略低。对于怀疑宫内生长迟缓、有早产风险的胎儿,应给予产前皮质类固醇,以改善围产期结局。
产前类固醇可降低 SGA 早产儿的死亡率和严重并发症。